Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

3 ETFs to Watch Out for on Biotech Earnings

Major players in the biotech space reported their second quarter 2017 results.

    Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View

    Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.

      Madhu Goel headshot

      Alexion (ALXN) Tops Q2 Earnings, Sales; Shares Up

      Alexion surpassed earnings and sales expectations in the second quarter of 2017.

        Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season

        Alexion Pharmaceuticals (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

          Can Intercept (ICPT) Beat Estimates this Earnings Season?

          Intercept Pharmaceuticals, Inc.'s (ICPT) lead drug Ocaliva's uptake has been encouraging and we expect the company to throw light on its label expansion when it reports second-quarter results.

            What's in the Cards for Exelixis (EXEL) in Q2 Earnings?

            Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.

              Is Celgene (CELG) Poised For a Beat This Earnings Season?

              Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.

                Are Options Traders Betting on a Big Move in Alexion Pharmaceuticals (ALXN) Stock?

                Investors in Alexion Pharmaceuticals, Inc. (ALXN) need to pay close attention to the stock based on moves in the options market lately.

                  Is a Beat in Store for Alexion (ALXN) this Earnings Season?

                  Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.

                    Is Gilead (GILD) Poised for a Beat This Earnings Season?

                    Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

                      Arpita Dutt headshot

                      Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

                      Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

                        Tirthankar Chakraborty headshot

                        5 Top Multibagger Biotech Stocks to Buy in the 2nd Half

                        Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.

                          Alexion Reportedly Being Investigated by HHS, Shares Slip

                          Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG).

                            Brian Hamilton headshot

                            Top Stock Reports for Oracle, Allergan & Abbott

                            Today's Research Daily features new research reports on 12 major stocks, including Oracle (ORCL), Allergan (AGN), and Abbott (ABT).

                              Company News for June 15, 2017

                              Companies in the News are: HRB,ALXN,UPS,NAME

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug

                                Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.

                                  Biogen Loses Top Executive Again, CFO Clancy to Join Alexion

                                  Biogen Inc.'s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month.

                                    Omeros (OMER) Lead Candidate Gets Breakthrough Designation

                                    Omeros Corporation (OMER) announced that the FDA granted breakthrough therapy designation to pipeline candidate OMS721.

                                      Why Is Alexion (ALXN) Down 23% Since the Last Earnings Report?

                                      Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Company News for May 24, 2017

                                        Companies in the News are: A,NOK,AAPL,ALXN,BG,GLEN

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data

                                          Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.

                                            Madeleine Johnson headshot

                                            Here's Why Alexion Pharma (ALXN) Stock is Sinking Today

                                            On Tuesday, shares of Alexion Pharmaceuticals Inc. (ALXN) are sinking, down over about 8.5% in mid-morning trading after the company announced a series of changes to its executive team.

                                              Alexion's (ALXN) Strensiq Results Positive in Long-Term Study

                                              Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

                                                Quite a few deals were announced this week including by companies like Biogen (BIIB).

                                                  Arpita Dutt headshot

                                                  Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death

                                                  Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.